Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495222 | 0.83 | MAP2K1 (0.46) | MAP2K1MAP2K2 | |
| SCHEMBL1555082 | 0.80 | ALDH1A1 (0.44) | MAP2K1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11909578 | 0.79 | MAP2K1 (0.50) | MAP2K1FLT1MAP2K2 | |
| SCHEMBL1681646 | 0.78 | MAP2K1 (0.49) | MAP2K1FLT1MAP2K2ALDH1A1MAPK1 | |
| SCHEMBL27162701 | 0.77 | MAPT (0.39) | MEN1KMT2ARAB9AMAPTHPGD | |
| SCHEMBL346016 | 0.76 | MAP2K1 (0.49) | MAP2K1FLT1MAP2K2 | |
| SCHEMBL971178 | 0.74 | GRIN2D (0.44) | MEN1KMT2ARAB9AMAPTALDH1A1 | |
| SCHEMBL13063527 | 0.74 | MAP2K1 (0.44) | MAP2K1FLT1MAP2K2 | |
| SCHEMBL345946 | 0.74 | MAP2K1 (0.51) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL11929737 | 0.73 | MAP2K1 (0.45) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2488507-B1 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2488507-B1 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2488507-A2 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | Allostem Therapeutics LLC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2012-08-16 | — | — | US | disclosed |
| WO-2011047055-A2 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047055-A2 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | MYLK2, MAPK1, MAP3K1 | MAP2K1 100/4885FLT1 1382/4885MAP2K2 80/4885 |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | NRAS, BRAF, MAP3K20 | MAP2K1 205/4885FLT1 1345/4885MAP2K2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.